about
Endothelin-1 as a central mediator of LPS-induced fever in ratsCentral endothelin ET(B) receptors mediate IL-1-dependent fever induced by preformed pyrogenic factor and corticotropin-releasing factor in the ratInterplay between miR-155, AT1R A1166C polymorphism, and AT1R expression in young untreated hypertensives.HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.Essential role for endothelin ET(B) receptors in fever induced by LPS (E. coli) in rats.Human amniotic fluid stem cell preconditioning improves their regenerative potential.Development of a website and biobank database for the Nanosized Cancer Polymarker Biochip Project: a Multicenter Italian Experience.Appropriateness of tumor marker request: a case of study.Epidemiology-based assessment of tumor marker overordering in breast cancer: an algorithm to examine different disease conditions.Indicators of inappropriate tumour marker use through the mining of electronic health records.Cyclooxygenase-independent mechanism of ibuprofen-induced antipyresis: the role of central vasopressin V₁ receptors.Increase of core temperature induced by corticotropin-releasing factor and urocortin: a comparative study.CCL3/macrophage inflammatory protein-1alpha induces fever and increases prostaglandin E2 in cerebrospinal fluid of rats: effect of antipyretic drugs.An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study.A comparative study of the antipyretic effects of indomethacin and dipyrone in rats.Testosterone and biological characteristics of breast cancers in postmenopausal women.Evaluation of a sex hormone-binding globulin automated chemiluminescent assay.An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests.Mirtazapine acutely inhibits basal and K(+)-stimulated release of corticotropin-releasing hormone from the rat hypothalamus via a non-genomic mechanism.Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 3).Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 2).Circulating tumor markers: a guide to their appropriate clinical use | Comparative summary of recommendations from clinical practice guidelines (PART 1)Hydroxyurea induces vasopressin release and cytokine gene expression in the rat hypothalamus.Regenerative medicine: an insight.Sirtuin 1 stabilization by HuR represses TNF-α- and glucose-induced E-selectin release and endothelial cell adhesiveness in vitro: relevance to human metabolic syndrome.Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determinationPhytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trialEvaluating Serum Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor Binding Protein 3 as Markers in Prostate Cancer DiagnosisCancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosisInflammation Markers: New Actors in the Cancer Biomarker TaleCirculating Sex Hormones and Tumor Characteristics in Postmenopausal Breast Cancer Patients. A Cross-Sectional StudyNew Frontiers in Tumor Marker Studies: From Biobanking to Collaboration in Translational ResearchEvaluation of cell-free DNA in urine as a marker for bladder cancer diagnosisEvaluation of cell-free DNA in urine as a marker for bladder cancer diagnosisEditor's comments: the role of inflammation in the development and progression of cancereditor's commentsELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumabShed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levelsDSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3'-End Usage
P50
Q28577151-BE14972C-95B5-4F21-8770-200D18723198Q28583837-242387EA-06A7-4FC1-A7F2-A42E6E6674DBQ34145150-F9A65A6D-F0AD-4B27-B4B3-8667606D0ABBQ34675374-4B154621-718C-45FD-B7A0-FC7E13916A5EQ35028056-181B4577-5E2C-407A-B11A-51B3E3BE34A0Q36093158-170264F3-35DB-44DC-BDCA-E5715D7AB10AQ38408155-4482A894-FDC2-47DC-89D7-2983C7A0A875Q38652521-F63D7F98-DC73-447B-96A8-F1ABD493F2B0Q38754409-97F6A28A-FDDB-4CB7-AB59-E514EA2173BCQ38786515-9534A1E1-463C-43C4-9DA5-C93A10BC35EDQ40343397-01329120-83A3-4B6A-8501-E9F2CBAFD8ACQ40351775-DF656435-367B-4BC4-B4B6-2E6B07E5D6B7Q40474760-D5004C14-60B0-46DF-A5EC-FA62B06D6538Q40560052-18C8E64A-F9FC-4C5B-9C07-4C986B0E64E9Q40588134-8FB0A668-93CB-462F-8051-43A492EB723CQ43258114-BC2F9EB6-7C5A-4FD5-B7EE-DB05983F6168Q44041311-866A5F7A-5D88-4CC8-8FC1-638BB62DFC6BQ44213777-2471728F-B945-4674-9415-4B4042C9D8D6Q45010770-A5D839D3-A68A-41BF-A868-34A3D0E08B29Q47883732-FCDA6973-1FC9-4237-A54A-F844D882F661Q47970538-6D8621EF-0218-42BC-BA83-864103525AC8Q48036378-02BAD478-00D0-4F1C-A1EE-424E69DC1196Q48470418-5816B929-AA00-4D8A-9495-5FF0924D7D0BQ50937798-64B9EA5B-F53F-4731-818B-308CA75BCCF1Q51743713-63345411-9F91-48AB-BC2F-ABDEA500EE3CQ55302514-AC089CA6-9D23-4C4A-A5ED-DAE3A9582DDDQ58487843-86FDE389-9F98-4E43-8156-E31E958B1DEFQ58487847-7B7661E5-4B81-41AC-99B2-F5DF1F997F30Q58487856-1C920B99-BEE4-4548-99F7-EEE31EDBD763Q58487862-E87C148F-7F08-4C70-AF70-5E18DC878C2CQ58487867-DD25AF0E-8248-4423-9F8C-75800B99D96FQ58487872-DB0AD203-F51A-451B-82D2-7B6343D22BC3Q58487879-075F89DD-4D4F-4582-8AB0-043EF3F8512CQ58487885-BFC31616-947E-4516-B99D-6BC57B75720FQ58487886-38E372CE-93CE-463D-8821-ED2C4A823DD9Q58487887-FC16AB46-FCF5-4CF2-B1F0-820097FE9F1DQ58487888-A9AA9AC8-DA6B-4B75-91AD-80DC97A7D4F9Q89810503-BDE70376-0F53-40EA-8849-F46FBFE2DA27Q93078883-CB3B950B-70D1-4DC8-843D-94D5A3D62483Q96168633-A5F68DF2-BE93-4DF2-B17E-C5471327046D
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Aline S C Fabricio
@ast
Aline S C Fabricio
@en
Aline S C Fabricio
@es
Aline S C Fabricio
@nl
type
label
Aline S C Fabricio
@ast
Aline S C Fabricio
@en
Aline S C Fabricio
@es
Aline S C Fabricio
@nl
altLabel
AS Fabricio
@en
ASC Fabricio
@en
Aline S C Fabricio
@en
Aline Sueli Coelho Fabricio
@en
Coelho Fabricio AS
@en
Coelho Fabricio Aline Sueli
@en
Fabricio AS
@en
Fabricio ASC
@en
Fabricio Aline Sueli Coelho
@en
prefLabel
Aline S C Fabricio
@ast
Aline S C Fabricio
@en
Aline S C Fabricio
@es
Aline S C Fabricio
@nl
P106
P1153
6602501594
P21
P31
P496
0000-0003-0153-8809